Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among US Community Hematologists/ Oncologists (cH/O)

被引：0
|
作者：
Gajra, Ajeet
Rathish, Yamini S.
Jeune-Smith, Yolaine
Klink, Andrew J.
Feinberg, Bruce
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia
    Chen, Xiao
    Chen, Xia
    Zhao, Sishu
    Shi, Yu
    Zhang, Ninghan
    Guo, Zhen
    Qiao, Chun
    Jin, Huimin
    Zhu, Liying
    Zhu, Huayuan
    Li, Jianyong
    Wu, Yujie
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2024, 106 (03) : 181 - 191
  • [42] Immunoglobulin kappa gene locus rearrangements in lambda light chain expressing B cell chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
    Belessi, C
    Stamatopoulos, K
    Hadzidimitriou, A
    Stavroyianni, N
    Tsompanakou, A
    Kalagiakou, E
    Paterakis, G
    Papadaki, T
    Athanasiadou, A
    Kokkini, G
    Douka, V
    Athanasiadou, I
    Lalayanni, C
    Saloum, R
    Fassas, A
    Anagnostopoulos, A
    Laoutaris, N
    BLOOD, 2003, 102 (11) : 351B - 351B
  • [43] A phase I/II multi-center study of Troxatyl™ in patients with refractory chronic lymphocytic leukemia (CLL), lymphoma or multiple myeloma (MM).
    Giles, F
    Belanger, R
    Toor, A
    McLaughlin, P
    Fayad, L
    Beran, M
    Albitar, M
    Vose, J
    BLOOD, 2001, 98 (11) : 289B - 289B
  • [44] Practice Mapping in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL): The Use of Measurable Residual Disease (MRD) Assessment in Real-World US Community Oncology Practice
    Welch, Verna L.
    Klink, Andrew J.
    Loberiza, Fausto R., Jr.
    Neuhof, Alexander
    Lord, Kevin
    Feinberg, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S189 - S189
  • [45] Quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) in Germany (QS-SID)
    Link, H.
    Holtmann, L.
    Kerkmann, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 197 - 198
  • [46] Different significance of minimal residual disease (MRD) after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia (CLL):: Prognostic and therapeutic implications.
    Esteve, J
    Villamor, N
    Colomer, D
    Rovira, M
    Bosch, F
    Cervantes, F
    López-Guillermo, A
    Bladé, J
    Montoto, S
    Urbano-Ispizua, A
    Carreras, E
    Montserrat, E
    BLOOD, 2001, 98 (11) : 763A - 763A
  • [47] Coincidence of chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) in one patient:: An exceptional or common event?: Summary of 4 cases at a single center.
    Rawluk, Justyna
    Schroettner, Percy
    Denz, Ullrich
    Pfeifer, Dietmar
    Pantic, Milena
    Veelken, Hendrik
    Engelhardt, Monika
    BLOOD, 2006, 108 (11) : 333B - 333B
  • [48] Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
    Rémi Letestu
    Abdelmalek Dahmani
    Marouane Boubaya
    Lucile Baseggio
    Lydia Campos
    Bernard Chatelain
    Agathe Debliquis
    Bernard Drénou
    Marie-Christine Jacob
    Eric Legac
    Magali Le Garff-Tavernier
    Anne-Catherine Lhoumeau
    Claire Quiney
    Nelly Robillard
    Michel Ticchioni
    Carmen Aanei
    Sandrine Katsahian
    Roselyne Delepine
    Sandrine Vaudaux
    Valérie Rouillé
    Marie-Christine Béné
    Caroline Dartigeas
    Eric Van Den Neste
    Stéphane Leprêtre
    Pierre Feugier
    Guillaume Cartron
    Véronique Leblond
    Vincent Lévy
    Florence Cymbalista
    Leukemia, 2021, 35 : 1597 - 1609
  • [49] Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
    Letestu, Remi
    Dahmani, Abdelmalek
    Boubaya, Marouane
    Baseggio, Lucile
    Campos, Lydia
    Chatelain, Bernard
    Debliquis, Agathe
    Drenou, Bernard
    Jacob, Marie-Christine
    Legac, Eric
    Le Garff-Tavernier, Magali
    Lhoumeau, Anne-Catherine
    Quiney, Claire
    Robillard, Nelly
    Ticchioni, Michel
    Aanei, Carmen
    Katsahian, Sandrine
    Delepine, Roselyne
    Vaudaux, Sandrine
    Rouille, Valerie
    Bene, Marie-Christine
    Dartigeas, Caroline
    van den Neste, Eric
    Lepretre, Stephane
    Feugier, Pierre
    Cartron, Guillaume
    Leblond, Veronique
    Levy, Vincent
    Cymbalista, Florence
    LEUKEMIA, 2021, 35 (06) : 1597 - 1609
  • [50] Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)
    Kovacs, Gabor
    Boettcher, Sebastian
    Bahlo, Jasmin
    Kluth, Sandra
    Ritgen, Matthias
    Fink, Anna Maria
    Stodden, Irene
    Cramer, Paula
    von Tresckow, Julia
    Maurer, Christian
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara
    BLOOD, 2014, 124 (21)
12345